Annual Financial Reports - 30 June 2022, 30 June 2023
Released
Released
Announcement PDF
BRING BACK SPONTANIETY
LTR Pharma Limited
ABN 64 644 924 569
Annual Financial Report
30 June 2022
LTR Pharma Limited
Contents
30 June 2022
Directors’ report
Auditor’s independence declaration
Statement of profit or loss and other comprehensive income
Statement of financial position
Statement of changes in equity
Statement of cash flows
Notes to the financial statements
Directors' declaration
Independent auditor's report
1
5
6
7
8
9
10
24
25
LTR Pharma Limited
Directors' report
30 June 2022
The directors present their report, together with the financial statements, of LTR Pharma Limited and the entities it controlled
(referred to hereafter as the ‘company’ or ‘entity’) for the year ended 30 June 2022.
Directors
The following persons were directors of the company during the whole of the financial year and up to the date of this report,
unless otherwise stated:
Lee Rodne
Julian Chick
Maja McGuire appointed 6 September 2021
Name:
Title:
Experience and expertise:
Lee Rodne
Executive Chairman
Lee holds over 25 years’ experience in the healthcare and technology
sectors and has been in executive leadership roles in both Public and
Private enterprises.
He previously worked in Fortescue Metals Group and led a healthcare
technology spin out (Allied Medical) as its CEO and Managing Director
that resulted in increasing its valuation from $800k to a peak of $250m
(ASX:AHZ, AVR).
Special responsibilities:
Name:
Title:
Experience and expertise:
Special responsibilities:
Name:
Title:
Experience and expertise:
He was also the Senior Executive of Sirius Minerals Plc that led to its
lead acquisition project and reached a peak market capitalisation of over
$1 billion on the London exchange. Lee holds an MBA from the
University of St Thomas, Minnesota and B.A. degree in Business
Management from St John’s University
None
Julian Chick
Non-Executive Director
Julian is an experienced healthcare executive with over 20 years’
experience in senior management and board positions including in ASX
listed companies Avexa (ASX:AVX) and Admedus (ASX: AHZ, AVR). He
has eight years’ investment banking experience and has also held a role
as an analyst reviewing healthcare and biotechnology investment
opportunities for private equity investors and venture capitalists. Julian
has a PhD in Physiology and is currently Chair of ASX listed digital health
company Opyl (ASX:OPL).
None
Maja McGuire
Non-Executive Director
Maja is an Australian qualified lawyer with almost 15 years’ experience in
the provision of corporate and compliance advice to ASX listed public
companies. This includes working with listed companies as a nonexecutive director, general counsel, company secretary and in private
practice.
Maja commenced her career as a corporate lawyer at top tier Clayton Utz,
before joining the Canadian Bankers Association in Toronto as a Financial
Advisor. Between 2014 – 2018, Maja was both Company Secretary and
Legal Counsel of previously named Admedus Limited (now Anteris
Technologies Ltd ASX:AVR), a global healthcare company focused on
developing, commercialising, manufacturing and distributing next
generation medical technologies and devices. Subsequently, between
2018 – 2020, Maja undertook the role of Company Secretary and Legal
Counsel at US based Alexium International Group Limited (ASX: AJX), a
company which holds proprietary patent applications for novel
technologies developed to provide thermal regulation and flame
1
LTR Pharma Limited
Directors' report
30 June 2022
retardancy. Maja continues her career as a corporate consultant and
brings extensive experience in ASX Listing Rule and Corporations Act
compliance, capital raisings, corporate governance, general commercial
contracts and dispute resolution.
Special responsibilities:
Maja is currently the non-executive chair of ASX listed TechGen Metals
(ASX:TG1), non-executive director of Kuniko (ASX:KNI) and nonexecutive director of OliveX (NSX: OLX). She holds BComm and LLB
qualifications from The University of Western Australia.
None
Company secretary
Automic Legal Pty Ltd has held the role of Company Secretary since July 2021.
Meetings of directors
No formal Board meetings were held by the Board of Directors during the financial year. The business of the Company was
conducted via a number of circular resolutions on relevant matters during the period.
Principal activities
During the financial year the principal continuing activities of the company consisted of:
●
Commercialising a ‘First in Class’ rapid onset on-demand PDE5 Inhibitor nasal spray product (SDS089)
●
Continued Research & Development of SDS089
●
Preparation for FDA Clinical Bridging Studies
Operating Result
The operating result for the year was as follows:
Loss before Income Tax
Income Tax (Expense)/Benefit
Loss for the Year
30 June 2022
$
(1,027,121)
(1,027,121)
30 June 2021
$
(40,803)
(40,803)
Dividends
No dividend was paid during the year and the Board has not recommended the payment of a dividend.
Review of operations
LTR Pharma Limited is commercialising a ‘First in Class’ rapid onset, on-demand Nasal Spray treatment for Erectile
Dysfunction (ED). The LTR Pharma product (SDS089) has completed a successful Human Proof of Concept study targeting
a rapid onset of effect in approximately 10-15 minutes compared to 60 minutes typical of oral administration of ED drugs like
Levitra and Viagra. LTR Pharma has a proprietary nasal delivery formulation to allow for a lower dose (less active ingredient),
fast acting administration (nasal as opposed to processed orally that needs to pass through the liver), which potentially
reduces the health risks that can be associated with ED drugs
The Global Erectile Dysfunction (ED) market is large and current drugs and methods to treat ED have hardly seen any
change over the past 25 years and is ready for new technology centred change. Patents of major market players have lapsed
over the last few years. This brings an exciting opportunity to bring to market a new fast acting, on demand treatment for ED.
The financial position of the entity is strong, and it could if required, access additional financial support from the majority
shareholder in the future. The SDS continuing development loan has been fully funded and the majority shareholder utilized
to fund the commitment was converted into equity in September 2021 with a balance of $359,500. As at the 30th of June
there are no outstanding borrowings. There are no bank borrowings or other material liabilities.
During the 2021-22 FY LTR Pharma has continued to progress with execution of the commercialisation plan for (SDS089)
and has achieved several key milestones. These milestones include:
•
•
•
Engaged with Global Nasal Spray Device Leader, APTAR for services including product optimisation and
manufacturing method development studies.
The Australian based CRO (Southern Star) was engaged for conducting the company’s upcoming human clinical
study and the protocol development for this study was primarily completed.
Australian manufacturing experts (Mayne Pharma) were formally contracted for clinical trial product manufacturing
2
LTR Pharma Limited
Directors' report
30 June 2022
•
•
•
Progressed the SDS089 formula optimisation process via the Aptar / Nanopharm Ltd. group
Early acceptance was issued from IP Australia for our product trademark “SPONTAN™”.
Completed a secondary fund raising at $0.14 per share raising an additional $600,000.
Significant changes in the state of affairs
The company completed a capital raising of $1,847,210 during the start of the year, as well as a secondary capital raising
$600,000 in June 2022 and converted to a public unlisted company.
Matters subsequent to the end of the financial year
The impact of the Coronavirus (COVID-19) pandemic is ongoing and while it has not financially impacted the entity adversely
up to 30 June 2022, it is not practicable to estimate the potential impact, positive or negative, after the reporting date. The
situation is still developing and is dependent on measures imposed by the Australian Government and other countries, such
as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be
provided.
Other than the above events, no other matter or circumstance has arisen since the end of the financial year and the date of
this report that has significantly affected, or may significantly affect the company's operations, the results of those operations,
or the company's state of affairs in future financial years.
Likely developments and expected results of operations
Information on likely developments in the operations of the company and the expected results of operations have not been
included in this report because the directors believe it would be likely to result in unreasonable prejudice to the company.
Environmental regulation
The company is not subject to any significant environmental regulation under Australian Commonwealth or State law.
Shares under option
There were no unissued ordinary shares of the company under option outstanding at the date of this report.
Shares issued on the exercise of options
There were no ordinary shares of the company issued on the exercise of options during the year ended 30 June 2022 and
up to the date of this report.
Indemnity and insurance of officers
The company has indemnified the directors and executives of the company for costs incurred, in their capacity as a director
or executive, for which they may be held personally liable, except where there is a lack of good faith.
During the 2022 financial year, the company has been covered as a subsidiary of the majority shareholder which has paid a
premium in respect of a contract to insure the directors and executives of the company against a liability to the extent
permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the
amount of the premium.
Indemnity and insurance of auditor
The company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the
company or any related entity against a liability incurred by the auditor.
During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company
or any related entity.
Proceedings on behalf of the company
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf
of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility
on behalf of the company for all or part of those proceedings.
3
LTR Pharma Limited
Directors' report
30 June 2022
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on
page 4.
This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001
On behalf of the directors
___________________________
Lee Rodne
Chairman
21 September 2022
Brisbane
4
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the audit of the financial report of LTR Pharma Limited for the year ended 30
June 2022, I declare that to the best of my knowledge and belief, there have been no
contraventions of:
a)
the auditor independence requirements of the Corporations Act 2001 in relation to the
audit, and
b)
any applicable code of professional conduct in relation to the audit.
Perth, Western Australia
21 September 2022
M R Ohm
Partner
6
LTR Pharma Limited
Statement of profit or loss and other comprehensive income
30 June 2022
Consolidated Group
Note
30 June 2022 30 June 2021
$
$
Other Income
9,078
-
Interest income
238
11
(390,496)
-
(279,933)
(19,056)
(4,615)
-
(348,305)
-
(27)
(9,383)
(2,014)
(9,514)
Currency gains/(losses)
(11,047)
(2,861)
Loss before income tax
(1,027,121)
(40,803)
-
-
(1,027,121)
(40,803)
Other comprehensive income for the year
44,827
-
Total comprehensive income (loss) for the year
(982,294)
(40,803)
Continuing operations
Expenses
Employee benefits expense
Consultancy and legal fees
Office and administrative costs
3
Research and development expense
Finance costs
Other expenses
4
Income tax expense
Loss after income tax expense for the year
The above statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
6
LTR Pharma Limited
Statement of financial position
As at 30 June 2022
Consolidated Group
Note
As at 30
June 2022
As at 30
June 2021
$
$
ASSETS
CURRENT ASSETS
Cash and cash equivalents
5
1,911,397
146,413
Other assets
6
43,295
-
1,954,692
146,413
290,680
276,287
TOTAL NON-CURRENT ASSETS
290,680
276,287
TOTAL ASSETS
2,245,372
422,700
465,906
1,000
TOTAL CURRENT ASSETS
NON-CURRENT ASSETS
Trade and other receivables
6
LIABILITIES
CURRENT LIABILITIES
Trade and other payables
Borrowings
8
-
359,503
Other liabilities
7
10,000
103,000
TOTAL CURRENT LIABILITIES
475,906
463,503
TOTAL LIABILITIES
475,906
463,503
NET ASSETS / (LIABILITIES)
1,769,466
(40,803)
EQUITY
Issued capital
8
2,792,563
-
Reserves
8
44,827
-
Accumulated losses
9
(1,067,924)
(40,803)
1,769,466
(40,803)
TOTAL EQUITY / (DEFICIENCY)
The above statement of financial position should be read in conjunction with the accompanying notes
7
LTR Pharma Limited
Statement of changes in equity
30 June 2022
Accumulated
losses
Foreign
currency
translation
reserve
Total
$
$
$
$
-
-
-
-
Loss for the year
-
(40,803)
-
(40,803)
Total comprehensive (loss) for
the year
-
(40,803)
-
(40,803)
Balance at 30 June 2021
-
(40,803)
-
(40,803)
Ordinary
Share
Capital
Accumulated
losses
Foreign
currency
translation
reserve
Total
$
$
$
$
-
(40,803)
-
(40,803)
Loss for the year
-
(1,027,121)
-
(1,027,121)
Currency translation differences
-
-
44,827
44,827
Total comprehensive loss for
the year
-
(1,027,121)
44,827
(982,294)
Consolidated Group
Note
Balance at 7 October 2020
Ordinary
Share
Capital
Comprehensive income
Consolidated Group
Note
Balance at 1 July 2021
Comprehensive (loss)
Transactions with owners, in
their capacity as owners, and
other transfers
Capital raising fees
(138,218)
(138,218)
Shares placement
2,447,210
-
-
2,447,210
Loan conversion LTR Medical
359,500
-
-
359,500
Settlement of advisory fees
124,071
-
-
124,071
Total transactions with owners
and other transfers
2,792,563
-
-
2,792,563
Balance at 30 June 2022
2,792,563
(1,067,924)
44,827
1,769,466
The above statement of changes in equity should be read in conjunction with the accompanying notes
8
LTR Pharma Limited
Statement of cash flows
For the year ended 30 June 2022
Consolidated Group
Note
As at 30
June 2022
As at 30
June 2021
$
$
238
11
(577,468)
(29,077)
Interest paid
(27)
-
R&D tax incentives received
9,078
-
(568,179)
(29,066)
Proceeds from issue of shares
2,344,210
-
Equity raising funds in advance
-
103,000
Proceeds from borrowings
-
350,120
Loans advanced
-
(274,780)
Net cash (used in)/generated by financing activities
2,344,210
178,340
Cash and cash equivalents at beginning of year
146,413
-
Net increase/(decrease) in cash held
1,776,031
149,274
Effects of exchange rate changes on cash and cash equivalents
(11,047)
(2,861)
1,911,397
146,413
CASH FLOWS FROM OPERATING ACTIVITIES
Interest income
Payments to suppliers and employees
Net cash (used in)/generated by operating activities
CASH FLOWS FROM FINANCING ACTIVITIES
Cash and cash equivalents at end of year
5
The above statement of cash flows should be read in conjunction with the accompanying notes
9
LTR Pharma Limited
Notes to the financial statements
30 June 2022
Note 1. Significant accounting policies
General information
The financial statements cover “LTR Pharma” or the “company” during the year ended 30 June 2022. The financial
statements are presented in Australian dollars, which is LTR Pharma Limited’s functional and presentation currency.
LTR Pharma Limited is a company limited by shares, incorporated, and domiciled in Australia. Its registered office and
principal place of business are:
Registered office & principal place of business
Registered office
9A/204 Alice Street
Brisbane
A description of the nature of the company's operations and its principal activities are included in the directors' report, which
is not part of the financial statements.
The financial statements were authorized for issue, in accordance with a resolution of directors, on 21 September 2022. The
directors have the power to amend and reissue the financial statements.
The principal accounting policies adopted in the preparation of the financial statements are set out below.
New and amended standards adopted by the Company
There were no new standards effective for the first time for years beginning on or after 1 July 2021 that have had a significant
effect on the Company’s financial statements.
New standards, amendments and interpretations not yet adopted
Any standards and interpretations that have been issued but are not yet effective, and that are available for early application,
have not been applied by the Company in these financial statements. There would be no material impact of those issued but
not yet effective standards on the financial statements. International Financial Reporting Standards that have recently been
issued or amended but are not yet effective have not been adopted for the reporting year ended 30 June 2022.
Basis of preparation
These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and
Interpretations issued by the AASB and the Corporations Act 2001, as appropriate for for-profit oriented entities. These
financial statements also comply with International Financial Reporting Standards (IFRS) as issued by the International
Accounting Standards Board ('IASB').
Historical cost convention
The financial statements have been prepared under the historical cost convention, except for, where applicable, certain
classes of property, plant and equipment and derivative financial instruments.
Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires
management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a
higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial
statements, are disclosed in note 2.
10
LTR Pharma Limited
Notes to the financial statements
30 June 2022
Note 1. Significant accounting policies (continued)
Going concern
The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business
activities and realization of assets and discharge of liabilities in the ordinary course of business.
As disclosed in the financial statements, the Company incurred a net loss of $1,027,121 and had net cash inflows of
$1,776,031 for the financial year ended 30 June 2022. As at that date, the Company had cash balances of $1,911,397 and
net assets of $1,769,466.
The Directors believe that it is reasonably foreseeable that the Company will continue as a going concern and that it is
appropriate to adopt the going concern basis in the preparation of the financial report after consideration of the following
factors:
•
Majority shareholder LTR Medical Limited has converted their loan to equity.
•
The company has successfully raised capital twice (at increasing valuation) in FY2022 for the company's research
and development including manufacturing preparation for clinical bridging studies, advancing plans for an expedited
FDA approval pathway, providing working capital and the costs of undertaking a potential IPO. As at the 21th of
September $2,447,210 has been received.
•
New partnerships and alliances.
•
Monitoring, management, and containment of discretionary costs, including R&D costs, and capital expenditures.
•
The Company’s cash flow forecasts that incorporate some but not all the above factors, thus providing some upside
sensitivity, indicated that the Company will be in a positive cash position during twelve months from the date of
approval of this report
Accordingly, the Directors believe that the Company will be able to continue as a going concern and that it is appropriate to
adopt the going concern basis in the preparation of the financial report.
Segment reporting
AASB 8 Operating segments requires operating segments to be identified on the basis of internal reports about components
of the Company that are regularly reviewed by the Chief Operating Decision Makers in order to allocate resources to the
segment and to assess its performance.
The company operates one segment this has been determined with reference to the monthly management accounts used by
the Chief Operating Decision Maker to make decisions regarding the Company’s operations and allocation of working capital.
Due to the size and nature of the Company, the Board as a whole has been determined as the Chief Operating Decision
Maker.
Foreign currency translation
The financial statements are presented in Australian dollars, which is LTR Pharma Limited's functional and presentation
currency.
Foreign currency transactions
Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the
transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation
at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in
profit or loss.
11
LTR Pharma Limited
Notes to the financial statements
30 June 2022
Note 1. Significant accounting policies (continued)
Revenue recognition
Revenue is recognized when it is probable that the economic benefit will flow to the entity and the revenue can be reliably
measured. Revenue is measured at the fair value of the consideration received or receivable.
Revenue and Other Income
To determine whether to recognize revenue, the Company follows a 5-step process:
1. Identifying the contract with a customer
2. Identifying the performance obligations
3. Determining the transaction price
4. Allocating the transaction price to the performance obligations
5. Recognizing revenue when/as performance obligation(s) are satisfied.
The revenue and profits recognized in any year are based on the delivery of performance obligations and an assessment of
when control is transferred to the customer.
Revenue is recognized either when the performance obligation in the contract has been performed, so 'point in time'
recognition or 'over time' as control of the performance obligation is transferred to the customer.
The nature of performance obligations categorized within this revenue type includes delivery of the order or alternatively
collection by customer, being ‘point in time’ when performance obligation is performed, control is transferred to the customer
and revenue is recognized at the transaction price.
Interest revenue is recognized using the effective interest method, which for floating rate financial assets is the rate inherent
in the instrument.
Refundable R&D tax offsets that relate to R&D expenditure which has been expensed are recognised in income within profit
or loss.
Dividend revenue is recognized when the right to receive a dividend has been established.
All revenue is stated net of the amount of goods and services tax.
Income tax
The income tax expense or benefit for the year is the tax payable on that year's taxable income based on the applicable
income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary
differences, unused tax losses and the adjustment recognised for prior years, where applicable.
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the
assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:
●
●
When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a
transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor
taxable profits; or
When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the
timing of the reversal can be controlled, and it is probable that the temporary difference will not reverse in the foreseeable
future.
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that
future taxable amounts will be available to utilise those temporary differences and losses.
The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax
assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the
carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable
that there are future taxable profits available to recover the asset.
Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against
current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on
either the same taxable entity or different taxable entities which intend to settle simultaneously.
12
LTR Pharma Limited
Notes to the financial statements
30 June 2022
Note 1. Significant accounting policies (continued)
Current and non-current classification
Assets and liabilities are presented in the statement of financial position based on current and non-current classification.
An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the company's
normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the
reporting year; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for
at least 12 months after the reporting year. All other assets are classified as non-current.
A liability is classified as current when: it is either expected to be settled in the company's normal operating cycle; it is held
primarily for the purpose of trading; it is due to be settled within 12 months after the reporting year; or there is no unconditional
right to defer the settlement of the liability for at least 12 months after the reporting year. All other liabilities are classified as
non-current.
Deferred tax assets and liabilities are always classified as non-current.
Cash and cash equivalents
Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term, highly
liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and
which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash
and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement
of financial position.
Trade and other receivables
Trade and other receivables include amounts due from customers for goods sold and services performed in the ordinary
course of business. Receivables expected to be collected within 12 months of the end of the reporting year are classified as
current assets. All other receivables are classified as non-current assets.
Trade and other receivables are initially recognized at fair value and subsequently measured at amortized cost using the
effective interest method, less any allowance for expected credit losses.
Trade and other payables
These amounts represent liabilities for goods and services provided to the company prior to the end of the financial year and
which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts
are unsecured and are usually paid within 30 days of recognition.
Borrowings
Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They
are subsequently measured at amortised cost using the effective interest method
Finance costs
Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in
the year in which they are incurred.
Provisions
Provisions are recognised when the company has a present (legal or constructive) obligation due to a past event, it is
probable the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the
obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present
obligation at the reporting date, considering the risks and uncertainties surrounding the obligation. If the time value of money
is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision
resulting from the passage of time is recognised as a finance cost.
Fair value measurement
When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair
value is based on the price that would be received to sell an asset or paid to transfer a liability in an
Share your feedback
Discover